Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lymphoproliferative Disorder Following Transplantation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07034755
What this trial is testing

Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)Chimeric Antigen Receptor T-cell
The Affiliated Hospital of Xuzhou Medical University 20
Not applicableStudy completedNCT04189835
What this trial is testing

EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients

Who this might be right for
EBV InfectionEBV ViremiaEpstein-Barr Virus Associated Lymphoproliferative Disorder+1 more
University of Aarhus 509
Early research (Phase 1)Study completedNCT02955550
What this trial is testing

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Celularity Incorporated 15
Large-scale testing (Phase 3)Ended earlyNCT00573391
What this trial is testing

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Who this might be right for
Multiple Myeloma
University of Arkansas 5
Testing effectiveness (Phase 2)Study completedNCT00925821
What this trial is testing

Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Wuerzburg University Hospital 146
Testing effectiveness (Phase 2)Study completedNCT00559104
What this trial is testing

Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 60
Testing effectiveness (Phase 2)WithdrawnNCT01812720
What this trial is testing

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
Mayo Clinic
Testing effectiveness (Phase 2)Study completedNCT00702403
What this trial is testing

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlastic Phase Chronic Myelogenous Leukemia+11 more
Fred Hutchinson Cancer Center 40
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)WithdrawnNCT03100877
What this trial is testing

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Who this might be right for
Plasma Cell Leukemia in RemissionPlasma Cell Myeloma
City of Hope Medical Center
Testing effectiveness (Phase 2)UnknownNCT01333605
What this trial is testing

IGEV Followed by Autologous Transplantation for Refractory or Relapsed Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Fudan University 43
Testing effectiveness (Phase 2)Ended earlyNCT01044745
What this trial is testing

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+108 more
University of Nebraska 20
Testing effectiveness (Phase 2)Study completedNCT00003146
What this trial is testing

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fred Hutchinson Cancer Center
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Testing effectiveness (Phase 2)Study completedNCT00310037
What this trial is testing

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Who this might be right for
Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology 151
Testing effectiveness (Phase 2)Study completedNCT00005802
What this trial is testing

Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

Who this might be right for
Leukemia
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)WithdrawnNCT03241017
What this trial is testing

Durvalumab in DLBCL After Autologous Transplant

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Insel Gruppe AG, University Hospital Bern
Early research (Phase 1)Ended earlyNCT00469820
What this trial is testing

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1
Large-scale testing (Phase 3)Ended earlyNCT00324324
What this trial is testing

Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant

Who this might be right for
Breast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more
OHSU Knight Cancer Institute 240
Testing effectiveness (Phase 2)WithdrawnNCT00723658
What this trial is testing

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Who this might be right for
Lymphoma
SWOG Cancer Research Network
Next Page